Focalyx Technologies Recalls Focalyx Fusion Software Due to Windows 10 Compatibility Risks
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Focalyx Technologies, LLC has issued a voluntary recall for Focalyx Fusion software devices because compatibility issues with Windows 10 may lead to patient harm or treatment delays.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references Worldwide. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, MedicalDevice.
What Happened
Focalyx Technologies, LLC. has initiated a voluntary recall of its Focalyx Fusion software device, an accessory used for image-guided interventional and diagnostic procedures involving the prostate. The recall was prompted by findings that certain accessories may not function properly when used with the Windows 10 operating system. This malfunction could potentially cause patient harm during biopsy procedures or result in significant delays in treatment and therapy.
Which Products Are Affected
The recall affects 18 units distributed worldwide, including the U.S. states of New York, Massachusetts, and Florida, as well as Spain, Venezuela, and the Dominican Republic.
- Product Name: Focalyx Fusion
- Recall Number: Z-1243-2026
- Software Versions: 1.3, 1.5, 1.6
- UDI-DI: 00860003552001
- Serial Numbers: IF-FF-B-1-22080504, IF-FF-B-1-TPAA998118, IF-FF-B-1-351238, IF-FF-B-1-TPAB081335, IF-FF-B-1-22080508, IF-FF-B-1-TPAB200331, IF-FF-B-1-TPAB200333, IF-FF-B-1-TPAC505383, IF-FF-B-1-TPAB200348, IF-FF-B-1-TPAB540364, IF-FF-B-1-S5ARQL009253NYZ, IF-FF-B-1-SCARQL0014096YZ, IF-FF-B-1-TPAB532163, IF-FF-B-1-SCARQL00136033KK, IF-FF-B-1-TPAB540359, IF-FF-B-1-TPAB081326, IF-FF-B-1-22080505, IF-FF-B-1-TPAB081324
What You Should Do
The firm is recommending that all users stop using the affected devices immediately. Use should only resume once the device has been verified and validated for compatibility with Windows 11. Focalyx Technologies initiated the notification process via letter on December 23, 2025.
Why This Matters
This recall is significant because software errors during prostate biopsies or diagnostic procedures can lead to direct physical harm to the patient or cause critical delays in necessary medical interventions.
Source
Information provided by the FDA.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.